Dr. Short is Chairman, CEO and Principal of BioAtla, LLC, a protein therapeutic service business based in San Diego and Beijing. He is the Founder and former CEO, President and CTO of Diversa Corp. (now British Petroleum and Verenium). Dr. Short also served as President of Stratacyte, and VP of R&D and Operations for Stratagene Cloning Systems (now Agilent). He has authored more than 100 publications and is the inventor of over 100 issued patents. In 2006, Dr. Short was shortlisted by the editors of Nature Biotechnology as a personality making the most significant contribution to biotech in the past decade. He is the recipient of numerous other awards, including American Chemical Society’s Henry F. Whalen, Jr. Award for Business Development, Adaptive Business Leaders’ Innovations in HealthCare Gold Award, and two of Connect’s Most Innovative Product Awards. Dr. Short’s board experience includes Invitrogen (now Life Technologies), Senomyx, Femta Pharmaceuticals, BioDuro (now PPD), Taxon Biosciences, Biotech Investment Group and Ciris Energy. He is a member of Young Presidents’ Organization/World Presidents’ Organization and a founder of Capia IP, VivaMab and the E.O. Wilson Biodiversity Foundation. Dr. Short also serves as an advisor to City National Bank, UCSD’s Division of Biology, Genalyte, San Diego Science Festival and SG Biofuels. He received his Ph.D. in Biochemistry from Case Western Reserve University.